Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase I/II trial studies the side effects and best dose of inotuzumab ozogamicin and to see how well it works when given together with combination chemotherapy in treating patients with acute lymphoblastic leukemia. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a toxic agent called N-acetyl-gamma-calicheamicin dimethyl hydrazide (CalichDMH). Inotuzumab attaches to CD22 positive cancer cells in a targeted way and delivers CalichDMH to kill them. Immunotherapy with monoclonal antibodies, such as blinatumomab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving inotuzumab ozogamicin together with combination chemotherapy may be a better treatment for acute lymphoblastic leukemia.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Pacjenci w wieku 60 lat lub starsi z nowo rozpoznaną białaczką lymphoblastyczną typu pre-B, z chromosomem Philadelphia lub bez niego
- •Pacjenci w wieku 18-60 lat w złym stanie ogólnym z nowo rozpoznaną białaczką lymphoblastyczną typu pre-B, którzy mają problemy zdrowotne (choroby serca, płuc, nerek lub wątroby)
- •Pacjenci w wieku 60+ lat niezdolni do intensywnej chemioterapii z powodu problemów zdrowotnych (choroby serca, cukrzyca, problemy z oddychaniem)
- •Stan ogólny pacjenta pozwalający na udział w badaniu (skala 0-3)
- •Prawidłowa funkcja wątroby i nerek, potwierdzająca bezpieczeństwo badania
- •Świadoma zgoda pacjenta na udział w badaniu
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 15, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
M D Anderson Cancer Center
Houston, United States
Trial contact
Elias Jabbour, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/16/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.